Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

NCT02954523 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

EGFR Gene Mutation
Nonsmall Cell Lung Cancer

Interventions

DRUG: Dasatinib
DRUG: Osimertinib

Sponsor

Chul Kim

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]